CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 16.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $60.000 thousand which missed the analyst consensus estimate of $1.524 million by 96.06 percent. This is a 63.41 percent decrease over sales of $164.000 thousand the same period last year.